These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19186005)

  • 21. Clinical outcome of dedifferentiated liposarcoma in the extremities: A retrospective case series of 7 patients.
    Kito M; Yoshimura Y; Isobe K; Aoki K; Suzuki S; Tanaka A; Okamoto M; Sano K; Kato H
    J Orthop Sci; 2016 Sep; 21(5):673-7. PubMed ID: 27317086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double minute chromosomes harboring MDM2 amplification in a pediatric atypical lipomatous tumor.
    Dadone-Montaudié B; Burel-Vandenbos F; Soler C; Rosello O; Boyer C; Fabas T; Bianchini L; Pedeutour F
    Genes Chromosomes Cancer; 2019 Sep; 58(9):673-679. PubMed ID: 30887579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
    Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
    Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma.
    Kobayashi A; Sakuma T; Fujimoto M; Jimbo N; Hirose T
    Appl Immunohistochem Mol Morphol; 2019; 27(10):758-763. PubMed ID: 31145104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features: a clinicopathological analysis of five cases].
    Si HP; Wang Z; Fan QH; Zhang YF; Yang DQ; Zhang ZH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):282-287. PubMed ID: 30955263
    [No Abstract]   [Full Text] [Related]  

  • 28. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
    Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
    Thway K; Flora R; Shah C; Olmos D; Fisher C
    Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
    Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.
    Knösel T; Altendorf-Hofmann A; Lindner L; Issels R; Hermeking H; Schuebbe G; Gibis S; Siemens H; Kampmann E; Kirchner T
    J Clin Pathol; 2014 Jul; 67(7):592-8. PubMed ID: 24747207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Well-differentiated and dedifferentiated liposarcomas.
    Coindre JM; Pédeutour F; Aurias A
    Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
    Boltze C; Schneider-Stock R; Jäger V; Roessner A
    Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dedifferentiated liposarcoma with meningothelial-like whorls, metaplastic bone formation, and CDK4, MDM2, and p16 expression: a morphologic and immunohistochemical study.
    Thway K; Robertson D; Thway Y; Fisher C
    Am J Surg Pathol; 2011 Mar; 35(3):356-63. PubMed ID: 21317707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation and aberrant promoter methylation of p16INK4A: a possible novel heritable susceptibility marker to retinoblastoma.
    Indovina P; Acquaviva A; De Falco G; Rizzo V; Onnis A; Luzzi A; Giorgi F; Hadjistilianou T; Toti P; Tomei V; Pentimalli F; Carugi A; Giordano A
    J Cell Physiol; 2010 Apr; 223(1):143-50. PubMed ID: 20039270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma.
    Taghavi N; Biramijamal F; Sotoudeh M; Khademi H; Malekzadeh R; Moaven O; Memar B; A'rabi A; Abbaszadegan MR
    BMC Cancer; 2010 Apr; 10():138. PubMed ID: 20388212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas.
    Ivanova TA; Golovina DA; Zavalishina LE; Volgareva GM; Katargin AN; Andreeva YY; Frank GA; Kisseljov FL; Kisseljova NP
    BMC Cancer; 2007 Mar; 7():47. PubMed ID: 17359536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma.
    Vos M; Boers R; Vriends ALM; Boers J; van Kuijk PF; van Houdt WJ; van Leenders GJLH; Wagrodzki M; van IJcken WFJ; Gribnau J; Grünhagen DJ; Verhoef C; Sleijfer S; Wiemer EAC
    PLoS One; 2020; 15(1):e0228014. PubMed ID: 31971976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.